Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.52
-0.46 (-3.51%)
At close: Apr 28, 2026, 4:00 PM EDT
12.54
+0.02 (0.20%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Contineum Therapeutics stock have an average target of 19, with a low estimate of 14 and a high estimate of 22. The average target predicts an increase of 51.82% from the current stock price of 12.52.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2026.
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $14 → $20 | Buy | Maintains | $14 → $20 | +59.81% | Mar 6, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $23 → $14 | Buy → Hold | Downgrades | $23 → $14 | +11.87% | Jan 8, 2026 |
| Baird | Baird | Buy Maintains $16 → $14 | Buy | Maintains | $16 → $14 | +11.87% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +75.79% | Nov 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $20 | Buy | Initiates | $20 | +59.81% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
6.12M
Revenue Next Year
2.24M
from 6.12M
Decreased by -63.33%
EPS This Year
-2.10
from -2.17
EPS Next Year
-2.22
from -2.10
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.5M | 11.6M | ||||||
| Avg | 6.1M | 2.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 88.7% | ||||||
| Avg | - | -63.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.34 | -1.77 | ||||||
| Avg | -2.10 | -2.22 | ||||||
| Low | -2.33 | -2.68 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.